Drug-eluting bead bronchial arterial chemoembolization vs. chemotherapy in treating advanced non-small cell lung cancer: comparison of treatment efficacy, safety and quality of life

X.-F. Liu, H. Lin, Q. Wang, M. Mu, P. Pan, F.-F. Tian, R. Zhang, W.-G. Zhao, P.-T. Bao

Department of Nuclear Medicine, The Eighth Medical Center of PLA General Hospital, Beijing, P.R. China. pengtaobao.309.hospital@qeejen.com

---

• Oncology

OBJECTIVE: This present study aimed to compare the treatment response, survival profile, quality of life (QoL), and safety between drug-eluting bead bronchial arterial chemoembolization (DEB-BACE) and chemotherapy in the treatment of advanced non-small-cell lung cancer (NSCLC).

PATIENTS AND METHODS: Totally, 44 advanced NSCLC patients were analyzed retrospectively and were divided into DEB-BACE group (n=23) and chemotherapy group (n=21). Treatment response, European Organization for Research and Treatment of Cancer QoL Questionnaire–Core 30 (EORTC QLQ-C30), progression-free survival (PFS), overall survival (OS), and adverse events were assessed during the follow-up.

RESULTS: At month (M) 2, M4 and M6 post initial treatment, objective response rate (ORR) was elevated (all p <0.05), and disease control rate (DCR) tended to be higher (without statistical significance) in DEB-BACE group compared with chemotherapy group. Regarding the QLQ-C30 item scores, the scores of physical functioning, role functioning, emotional functioning, cognitive functioning, social functioning were increased, while the scores of nausea and vomiting, dyspnea, constipation were decreased in DEB-BACE group compared with chemotherapy group (all p <0.05). Based on survival profile, DEB-BACE group achieved better PFS and OS compared with chemotherapy group independent of TNM stage, which was also supported by further subgroup analysis and Cox’s proportional hazard regression analysis (all p <0.05). Furthermore, two groups all exhibited mild and tolerable adverse events.

CONCLUSIONS: DEB-BACE has the potential to be an additional treatment option with favorable therapeutic efficacy, improved QoL, and tolerable safety for advanced NSCLC patients.

Free PDF Download